Novo Nordisk and UofT announce joint investment to address diabetes & chronic disease prevention
Novo Nordisk A/S and the University of Toronto (UofT) has announced a CAD 40 million investment to establish the Novo Nordisk Network for Healthy Populations, says a press release.
The network will focus on new ways to support healthier urban populations to impact the global fight against diabetes and other serious chronic diseases. The new network will be a partnership between the Dalla Lana School of Public Health, the Temerty Faculty of Medicine and the University of Toronto Mississauga.
"As we commemorate the 100th anniversary of the discovery of insulin at UofT, we are thrilled to once again partner with Novo Nordisk, a company that understands the vital importance of helping those living with diabetes and other chronic diseases," said UofT President Meric Gertler.
In 1921, a UofT research team of Frederick Banting, Charles Best, J.J.R. MacLeod and James Bertram Collip discovered insulin. Novo Nordisk predecessors, Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium, were among the first to produce insulin at a large scale, bringing this life-saving treatment from UofT labs to people with diabetes around the world.
Now, 100 years later, UofT and Novo Nordisk will once again work together to improve the lives of people living with diabetes.